Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

88.81
Delayed Data
As of May 25
 +0.86 / +0.98%
Today’s Change
62.12
Today|||52-Week Range
151.75
-15.23%
Year-to-Date
A 'What's Next?' Scenario for the Delayed Sarepta Duchenne Drug Review
May 25 / TheStreet.com - Paid Partner Content
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
May 16 / Zacks.com - Paid Partner Content
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
May 20 / Zacks.com - Paid Partner Content
3 Risky Biotechs With FDA Decisions On Deck -- Are They Buys?
May 12 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close87.95
Today’s open88.31
Day’s range87.50 - 89.85
Volume1,062,649
Average volume (3 months)1,722,496
Market cap$14.3B
Dividend yield--
Data as of 4:00pm ET, 05/25/2016

Growth & Valuation

Earnings growth (last year)-16.30%
Earnings growth (this year)-105.34%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+16.29%
P/E ratioNM
Price/Sales19.22
Price/Book5.92

Competitors

 Today’s
change
Today’s
% change
PRGOPerrigo Company PLC+0.31+0.32%
INCYIncyte Corp+1.89+2.33%
MDVNMedivation Inc-0.43-0.69%
JAZZJazz Pharmaceuticals...+1.08+0.71%
Data as of 4:02pm ET, 05/25/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)-$0.50
Annual revenue (last year)$872.2M
Annual profit (last year)-$171.8M
Net profit margin-19.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts

Partner Offers

Search for Jobs